Shomron Ben‐Horin

Research interests

Publications

• Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2021.02.068

• Deep learning for wireless capsule endoscopy: a systematic review and meta-analysis

  Gastrointestinal Endoscopy · 2020 · https://doi.org/10.1016/j.gie.2020.04.039

• Deep learning algorithms for automated detection of Crohn’s disease ulcers by video capsule endoscopy

  Gastrointestinal Endoscopy · 2019 · https://doi.org/10.1016/j.gie.2019.11.012

• Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

  Journal of Crohn s and Colitis · 2017 · https://doi.org/10.1093/ecco-jcc/jjx143

• Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease

  Journal of Gastroenterology · 2017 · https://doi.org/10.1007/s00535-017-1324-3

• Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.02.019

• Infliximab-Related Infusion Reactions: Systematic Review

  Journal of Crohn s and Colitis · 2015 · https://doi.org/10.1093/ecco-jcc/jjv096

• Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

  Gut · 2015 · https://doi.org/10.1136/gutjnl-2015-309290

• Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.10.025

• Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab

  Clinical Gastroenterology and Hepatology · 2014 · https://doi.org/10.1016/j.cgh.2014.07.029

• Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

  Gastroenterology · 2014 · https://doi.org/10.1053/j.gastro.2014.05.008

• Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

  Journal of Crohn s and Colitis · 2014 · https://doi.org/10.1016/j.crohns.2013.12.013

• Tailoring anti-TNF therapy in IBD: drug levels and disease activity

  Nature Reviews Gastroenterology & Hepatology · 2014 · https://doi.org/10.1038/nrgastro.2013.253

• Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

  Alimentary Pharmacology & Therapeutics · 2014 · https://doi.org/10.1111/apt.12869

• The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

  Gut · 2013 · https://doi.org/10.1136/gutjnl-2013-305259

• Optimizing anti-TNF treatments in inflammatory bowel disease

  Autoimmunity Reviews · 2013 · https://doi.org/10.1016/j.autrev.2013.06.002

• Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

  Inflammatory Bowel Diseases · 2012 · https://doi.org/10.1002/ibd.22902

• Anti-tumor necrosis factor and postoperative complications in Crohnʼs disease: systematic review and meta-analysis

  Inflammatory Bowel Diseases · 2012 · https://doi.org/10.1002/ibd.22954

• Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

  Clinical Gastroenterology and Hepatology · 2012 · https://doi.org/10.1016/j.cgh.2012.10.020

• Review article: loss of response to anti-TNF treatments in Crohn’s disease

  Alimentary Pharmacology & Therapeutics · 2011 · https://doi.org/10.1111/j.1365-2036.2011.04612.x

• The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

  Gut · 2010 · https://doi.org/10.1136/gut.2009.201533

• Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

  Journal of Crohn s and Colitis · 2010 · https://doi.org/10.1016/j.crohns.2010.04.004

Current projects

No projects listed.